In recent years, the approach to managing low-tumor-burden FL has evolved to include functional imaging techniques, such as 18F-FDG PET/CT, and molecular profiling of MRD and key genetic mutations (e.g., TP53, KMT2D, and EZH2), which allow for a more individualized and refined risk stratification [64]. Here, TP53 is linked to neoplasm.